We use cookies to ensure that we give you the best experience on our website. By using this website, you agree to this use. More information Close
Vienna Stock Exchange News

Vienna Stock Exchange welcomes Marinomed Biotech

  • New biotech company on the prime market of the Vienna Stock Exchange
  • Start of stock market trading: opening bell rings in initial price of EUR 75.50
  • Marinomed joins ATX prime and ATX global players index

(Vienna) With the successful initial public offering (IPO), the shares of Marinomed Biotech AG (ISIN: ATMARINOMED6) started trading in the top segment of the Vienna Stock Exchange today. The IPO of Marinomed Biotech AG is the first in Europe this year. Market supply and demand determined the first stock market price of 75.5 EUR. The market capitalisation of the globally-active Vienna-based biopharmaceutical company computed on the opening price was EUR 95.13 million (excl. greenshoe). On the second day of trading, Monday, 4 February 2019, Marinomed Biotech AG will be added to the indices "ATX prime" and "ATX global players".

The start of trading was traditionally celebrated with the bell-ringing ceremony. In his keynote speech, Marinomed CEO Andreas Grassauer said: "Our presence on the Vienna Stock Exchange and our dialogue with investors puts us in an even better position to achieve our growth targets. The IPO ensures the highest degree of international attention for our company”.

Christoph Boschan, CEO of the Vienna Stock Exchange and its holding company, said "Marinomed wants to conquer the world market. And we are a very international stock exchange and use the world's leading trading technology. So it is a wonderful fit."

More than eight out of ten euros traded daily on the Vienna Stock Exchange originate from international investment banks. An analysis of the free float on the prime market reveals that institutional investors from the United States, Austria, the United Kingdom, Norway and Germany hold the largest interests in Austrian equities.

According to the company, Marinomed's business focus is on the development of innovative products for respiratory and eye diseases based on patented technology platforms. The company's free float is around 31%. The IPO was underwritten by Erste Group Bank AG which also acts as a specialist for the stock to ensure high quality pricing.

Video from the 1st trading day
Photo gallery
Current price information

 

For further information, please contact:

Julia Resch

Julia Resch

julia.resch(a)wienerborse.at
T +43 1 531 65-186

Maria Zorn

Maria Zorn

maria.zorn(a)wienerborse.at
T +43 1 531 65-110

About the Vienna Stock Exchange

The Vienna Stock Exchange is the only securities exchange in Austria. It features a modern infrastructure and supplies market data and relevant information.  It offers Austrian companies maximum visibility, high liquidity and utmost transparency. Investors can rely on the smooth and efficient execution of exchange trades. The Vienna Stock Exchange operates a central market datafeed for Central and Eastern Europe (CEE) and is well established as an expert for the calculation of indices with a reference to the region. Wiener Börse AG, together with its holding company, CEESEG, cooperates with over ten exchanges in CEE and is globally recognized for this unique know-how.

Exclusion of Liability

This press release may contain certain forward-looking statements and forecasts that are based on assumptions current made at the time of publication of this press release. We do not assume any liability for these forward-looking statements materializing. Furthermore, we would like to explicitly point out that this press release cannot serve as a basis for investment decisions and may not be construed as a solicitation to buy or a recommendation to invest by Wiener Börse AG. No liability is assumed for the information given in this press release.